Tubastatin A was reported as selective HDAC6 inhibitor with neuroprotective activity56 and no study proved its potential antiproliferative activity against any type of cancer, but it increased the sensitivity of non-small cell lung cancer (NSCLC) to cisplatin.62 This evidence concerns the gene HDAC6 and non-small cell lung carcinoma.